Merus Labs International Inc. is a specialty pharmaceutical company engaged in the acquisition and licensing of niche pharmaceutical products throughout North America. By capitalizing on its expertise of the North American pharmaceutical markets and access to capital, Merus is currently focused on building its portfolio of products. Merus strategically develops the sale and distribution of their product line by introducing a targeted re-launch marketing and promotional plan. PowerOne was instrumental in the creation of the company and has helped Merus raise over $100M in Debt and Equity since its inception.
Visit Website
Investors 1
| Date | Name | Website |
| - | PowerOne C... | poweroneca... |
Mentions in press and media 6
| Date | Title | Description | Source |
| 30.04.2015 | Merus Labs closes $60-million bought-deal financing | April 30, 2015 An anonymous director reports | poweroneca... |
| 10.06.2013 | Merus Announces Closing of Private Placement | June 10, 2013 Merus Labs International Inc. (“Merus” or the “Company”) (TSX:MSL) (NASDAQ:MSLI) anno... | poweroneca... |
| 07.03.2012 | CRTX sells rights to two drugs, shifts focus to drugs sold i... | The deals also include Cornerstone’s oral antibiotic Spectracef, but no details on that transaction ... | medcitynew... |
| 14.10.2011 | Merus Labs International Inc. announces proceeds of the warr... | VANCOUVER, Oct. 14, 2011 /CNW/ – Merus Labs International Inc. (the “Company”) is pleased to announc... | poweroneca... |
| 23.03.2011 | Merus Labs International Inc. Announces Closing Of Non-Broke... | March 23, 2011 VANCOUVER, March 23 /CNW/ – Merus Labs International Inc. (“Merus” or the “Company”)... | poweroneca... |
| - | CRTX sells rights to two drugs, shifts focus to drugs sold i... | Cornerstone Therapeutics (NASDAQ:CRTX) has sold rights to two anti-infective products in deals that ... | medcitynew... |